ITGR · Integer Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.85B | $1.72B | $1.60B | $1.38B | $1.22B | $1.07B |
| Cost of Revenue | $1.35B | $1.26B | $1.18B | $1.02B | $884.11M | $787.74M |
| Gross Profit | $500.39M | $459.01M | $418.29M | $359.01M | $336.97M | $285.71M |
| R&D | $49.50M | $53.42M | $63.77M | $60.92M | $51.98M | $48.47M |
| SG&A | $211.75M | $185.20M | $175.62M | $160.58M | $141.42M | $109.01M |
| Total Operating Expenses | $279.12M | $250.78M | $250.96M | $237.68M | $201.26M | $165.09M |
| D&A | $130.67M | $111.03M | $98.84M | $91.99M | $81.37M | $79.32M |
| Operating Income | $221.26M | $208.24M | $167.33M | $121.33M | $135.71M | $120.61M |
| Interest Expense | $43.21M | $56.37M | $53.37M | $38.63M | $31.63M | $38.22M |
| Income Tax | $22.57M | $26.51M | $16.64M | $10.61M | $8.04M | $8.95M |
| Net Income | $102.81M | $119.90M | $90.65M | $66.38M | $96.81M | $77.26M |
| EPS - Basic | $2.96 | $3.57 | $2.72 | $2.00 | $2.93 | $2.35 |
| EPS - Diluted | $2.89 | $3.36 | $2.69 | $1.99 | $2.91 | $2.33 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.16M | $46.54M | $23.67M | $24.27M | $17.89M | $49.21M |
| Accounts Receivable | $346.08M | $245.27M | $238.28M | $224.32M | $182.31M | $156.21M |
| Inventory | $253.74M | $247.13M | $239.72M | $208.77M | $155.70M | $149.32M |
| Accounts Payable | $113.13M | $101.50M | $120.29M | $110.78M | $76.86M | $51.57M |
| Current Assets | $770.10M | $671.12M | $617.67M | $558.30M | $452.98M | $412.94M |
| Total Assets | $3.41B | $3.08B | $2.94B | $2.79B | $2.58B | $2.37B |
| Current Liabilities | $232.04M | $227.17M | $220.97M | $223.75M | $159.63M | $156.19M |
| Long-term Debt | $1.19B | $980.15M | $959.92M | $907.07M | $812.88M | $693.76M |
| Total Liabilities | $1.66B | $1.46B | $1.42B | $1.38B | $1.23B | $1.10B |
| Stockholders' Equity | $1.75B | $1.62B | $1.52B | $1.42B | $1.35B | $1.27B |
| Retained Earnings | $994.05M | $891.25M | $771.35M | $680.70M | $614.32M | $517.52M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $196.15M | $205.21M | $180.21M | $116.38M | $156.67M | $181.34M |
| Investing Cash Flow | ($270.73M) | ($195.41M) | ($163.37M) | ($200.42M) | ($271.00M) | ($56.58M) |
| Financing Cash Flow | $43.56M | $13.32M | ($18.01M) | $92.48M | $81.99M | ($88.58M) |
| CapEx | $91.03M | $105.36M | $119.94M | $74.73M | $53.46M | $46.83M |
| Free Cash Flow | $105.12M | $99.85M | $60.27M | $41.65M | $103.20M | $134.51M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 27.0% | 26.7% | 26.2% | 26.1% | 27.6% | 26.6% |
| Operating margin | 11.9% | 12.1% | 10.5% | 8.8% | 11.1% | 11.2% |
| EBITDA margin | 19.0% | 18.6% | 16.7% | 15.5% | 17.8% | 18.6% |
| Net margin | 5.5% | 7.0% | 5.7% | 4.8% | 7.9% | 7.2% |
| Free cash flow margin | 5.7% | 5.8% | 3.8% | 3.0% | 8.5% | 12.5% |
| FCF / Net income | 1.02 | 0.83 | 0.66 | 0.63 | 1.07 | 1.74 |
| R&D / Revenue | 2.7% | 3.1% | 4.0% | 4.4% | 4.3% | 4.5% |
| SG&A / Revenue | 11.4% | 10.8% | 11.0% | 11.7% | 11.6% | 10.2% |
| Effective tax rate | 18.0% | 18.1% | 15.5% | 13.8% | 7.7% | 10.4% |
| Return on assets | 3.0% | 3.9% | 3.1% | 2.4% | 3.7% | 3.3% |
| Return on equity | 5.9% | 7.4% | 6.0% | 4.7% | 7.1% | 6.1% |
| Return on invested capital | 6.2% | 6.6% | 5.7% | 4.5% | 5.8% | 5.5% |
| Liquidity | ||||||
| Current ratio | 3.32 | 2.95 | 2.80 | 2.50 | 2.84 | 2.64 |
| Quick ratio | 2.23 | 1.87 | 1.71 | 1.56 | 1.86 | 1.69 |
| Cash ratio | 0.07 | 0.20 | 0.11 | 0.11 | 0.11 | 0.32 |
| Leverage | ||||||
| Debt / Equity | 0.68 | 0.61 | 0.63 | 0.64 | 0.60 | 0.55 |
| Debt / Assets | 0.35 | 0.32 | 0.33 | 0.32 | 0.31 | 0.29 |
| Debt / EBITDA | 3.37 | 3.07 | 3.61 | 4.25 | 3.74 | 3.47 |
| Interest coverage | 5.1x | 3.7x | 3.1x | 3.1x | 4.3x | 3.2x |
| Equity multiplier | 1.95 | 1.90 | 1.94 | 1.97 | 1.91 | 1.87 |
| Liabilities / Assets | 0.49 | 0.47 | 0.48 | 0.49 | 0.48 | 0.46 |
| Efficiency | ||||||
| Asset turnover | 0.54 | 0.56 | 0.54 | 0.49 | 0.47 | 0.45 |
| Inventory turnover | 5.33 | 5.09 | 4.92 | 4.87 | 5.68 | 5.28 |
| Days sales outstanding | 68d | 52d | 54d | 60d | 54d | 53d |
| Days inventory outstanding | 68d | 72d | 74d | 75d | 64d | 69d |
| Days payable outstanding | 31d | 29d | 37d | 40d | 32d | 24d |
| Cash conversion cycle | 106d | 94d | 91d | 95d | 87d | 98d |
| Valuation | ||||||
| P / E | 27.1x | 39.4x | 36.8x | 34.4x | 29.4x | 34.8x |
| P / B | 1.6x | 2.9x | 2.2x | 1.6x | 2.1x | 2.1x |
| P / S | 1.5x | 2.8x | 2.1x | 1.7x | 2.3x | 2.5x |
| EV / EBITDA | 11.3x | 17.7x | 16.1x | 14.8x | 16.8x | 16.7x |
| Growth | ||||||
| Revenue growth (YoY) | 8.0% | 7.5% | 16.0% | 12.7% | 13.8% | -14.7% |
| Revenue CAGR (3y) | 10.4% | 12.0% | 14.2% | 3.0% | 0.2% | -9.8% |
| Revenue CAGR (5y) | 11.5% | 6.4% | 5.6% | -1.2% | -2.5% | 6.0% |
| Gross profit growth (YoY) | 9.0% | 9.7% | 16.5% | 6.5% | 17.9% | -19.5% |
| Operating income growth (YoY) | 6.3% | 24.4% | 37.9% | -10.6% | 12.5% | -23.5% |
| Net income growth (YoY) | -14.3% | 32.3% | 36.6% | -31.4% | 25.3% | -19.8% |
| EPS growth (YoY) | -14.0% | 24.9% | 35.2% | -31.6% | 24.9% | -20.2% |
| EPS CAGR (3y) | 13.2% | 4.9% | 4.9% | -12.0% | -17.3% | 3.7% |
| EPS CAGR (5y) | 4.4% | 2.8% | -12.2% | -1.0% | 72.6% | - |
| FCF growth (YoY) | 5.3% | 65.7% | 44.7% | -59.6% | -23.3% | 14.8% |
| FCF CAGR (5y) | -4.8% | -3.1% | -13.2% | -16.4% | 17.1% | - |
| Book value growth (YoY) | 7.9% | 6.6% | 7.2% | 4.6% | 6.6% | 10.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.85B totalReportable Segment$1.85B · 100.0%
Product / service
$1.85B totalCardio And Vascular$1.11B · 59.7%
Cardiac Rhythm Management Neuromodulation$668.80M · 36.1%
Other Markets$77.75M · 4.2%
Geographic
$1.85B totalUS$979.81M · 52.9%
Rest Of World$469.88M · 25.3%
CR$173.52M · 9.4%
PR$131.26M · 7.1%
IE$99.16M · 5.3%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.54
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing Integer Holdings Corp against the 5 most active filers in the same SIC group.